Back to today’s briefing

Story perspectives

CHLA Unveils Revolutionary Gene Therapy for Sickle Cell

2/8/2025

48 6

Summary

Story summary

Children’s Hospital Los Angeles (CHLA) is revolutionizing pediatric care with the introduction of Casgevy, a groundbreaking gene-editing therapy for sickle cell disease. Utilizing advanced CRISPR technology, this innovative treatment transforms blood stem cells to generate fetal hemoglobin. With the addition of Lyfgenia, CHLA solidifies its position as a pioneer in pediatric gene therapies on the West Coast.

1 of 1

Story summary

Children’s Hospital Los Angeles (CHLA) is revolutionizing pediatric care with the introduction of Casgevy, a groundbreaking gene-editing therapy for sickle cell disease. Utilizing advanced CRISPR technology, this innovative treatment transforms blood stem cells to generate fetal hemoglobin. With the addition of Lyfgenia, CHLA solidifies its position as a pioneer in pediatric gene therapies on the West Coast.